Spire’s invention provides Nano-PV devices having sizes in a range of about 50 nanometers to about five microns, and a method for their fabrication.
The devices functionalized to target specific cells and then are selectively activated by light to generate an electrical charge to kill or interfere with cell growth.
Spire chairman, CEO, and co-inventor Roger Little said this being the company’s third patent issued from its original invention in the biomedical field.
"This patent further strengthens our intellectual property portfolio in our optoelectronic and biomedical market areas," Little said.
Spire is a global solar company providing capital equipment and turn-key production lines to manufacture PV modules.
